Studies of NETs in COVID-19

Author, year Patients Biomarkers Method used in measurement of NETs Results
Nicolai et al., 2020 [37] 38 COVID-19 patients and 24 non-COVID-19 controls H3Cit, MPO Immunofluorescence NETs detected in inflammatory microvascular thrombi located in the lung, kidney, and heart
Zuo et al., 2020 [38] 22 COVID-19 patients who developed thrombosis and 22 COVID-19 patients without clinical thrombosis cfDNA, MPO, H3Cit Quant-iT Pico Green dsDNA Assay Kit (for dsDNA) and ELISA (for MPO and H3Cit) All NETs markers associated with higher risk of morbid thrombotic events
Middleton et al., 2020 [39] 33 COVID-19 patients and 17 healthy controls MPO ELISA Plasma MPO-DNA complexes significantly elevated in COVID-19 patients and correlated with illness severity
Veras et al., 2020 [40] 32 COVID-19 patients and 21 healthy controls MPO, H3Cit Immunostaining Neutrophils from COVID-19 patients released statistically higher levels of NETs compared with healthy controls

AIS, Acute Ischemic Stroke; dsDNA, double-stranded DNA; ELISA, Enzyme-Linked Immunosorbent Assay; NE, Neutrophil Elastase; MPO, myeloperoxidase; NET, Neutrophil Extracellular Traps; H3Cit, citrullinated histone H3; cfDNA, cell-free DNA.

Exp Neurobiol 2021;30:1~12
© Exp Neurobiol